{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:10:23Z","timestamp":1789139423383,"version":"build-2803163510"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA293642"],"award-info":[{"award-number":["R01CA293642"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["LC200107"],"award-info":[{"award-number":["LC200107"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Non\u2013small cell lung cancer (NSCLC) is responsible for the majority of cancer-related mortality worldwide. Lung adenocarcinoma is the most common NSCLC subtype. Despite advances in targeted therapies, treatment resistance remains a critical challenge. Ribonucleotide reductase (RNR), a crucial enzyme in deoxyribonucleotide triphosphate biosynthesis, is frequently upregulated in cancer, contributing to genomic instability and poor prognosis in multiple malignancies. However, the role of the RNR complex in driving tumorigenesis is not fully understood in oncogene-driven lung adenocarcinoma. Transcriptomic analysis of more than 27,000 real-world samples of patients with NSCLC revealed that RNR subunits (RRM1 and RRM2) are significantly upregulated in TP53-mutated NSCLC and are correlated with significantly poor prognosis in multiple oncogene-driven lung adenocarcinoma. Using pharmacologic and genetic approaches to inhibit RNR in lung adenocarcinoma models, we assessed functional consequences through molecular, biochemical, and imaging techniques. RNR inhibition induced appreciable replication stress and triggered DNA damage, leading to cell death in lung adenocarcinoma cells. Notably, we uncovered that RNR suppression preferentially induced ferroptosis, an iron-dependent cell death driven by lipid peroxidation. This represents a previously unrecognized mechanism of RNR-mediated cell death by which mutant lung adenocarcinoma cells can be selectively targeted. Our study establishes RNR inhibition as a potent strategy to selectively induce ferroptosis in oncogene-addicted lung adenocarcinoma, offering a new therapeutic avenue for genetically defined patient subgroups. Targeting nucleotide metabolism could serve as an effective approach to overcome treatment resistance and improve clinical outcomes for patients with high-risk lung adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our findings highlight RNR as a promising therapeutic target in oncogene-driven lung adenocarcinoma. By demonstrating that RNR inhibition induces ferroptosis, our study opens up new possibilities for developing targeted therapies that selectively eliminate cancer cells in lung adenocarcinoma, paving the way for personalized treatment strategies and potentially overcoming resistance to current therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0829","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:52:06Z","timestamp":1787953926000},"page":"2136-2148","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non\u2013Small Cell Lung Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-0357","authenticated-orcid":false,"given":"Utsav","family":"Sen","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Department of Oncological Sciences, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4221-0457","authenticated-orcid":false,"given":"Dalia","family":"Natour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Comprehensive Cancer Center 2 Division of Medical Oncology, Department of Internal Medicine, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-9011","authenticated-orcid":false,"given":"Subhamoy","family":"Chakraborty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Comprehensive Cancer Center 2 Division of Medical Oncology, Department of Internal Medicine, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-5836","authenticated-orcid":false,"given":"Elisa","family":"Gobbini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Comprehensive Cancer Center 2 Division of Medical Oncology, Department of Internal Medicine, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3628-9365","authenticated-orcid":false,"given":"Chih-wei","family":"Fan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Department of Oncological Sciences, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-0881","authenticated-orcid":false,"given":"Calvin","family":"Koelbel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Comprehensive Cancer Center 2 Division of Medical Oncology, Department of Internal Medicine, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 3 , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-2563","authenticated-orcid":false,"given":"Ari M.","family":"Vanderwalde","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 3 , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 4 Department of Hematology and Oncology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8360","authenticated-orcid":false,"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/044ntvm43","id-type":"ROR","asserted-by":"publisher"}],"name":"Montefiore Medical Center 5 , Albert Einstein College of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-0407","authenticated-orcid":false,"given":"Deniz","family":"Demircioglu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Department of Oncological Sciences, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 6 Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 7 Bioinformatics for Next Generation Sequencing (BiNGS) Core, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-1636","authenticated-orcid":false,"given":"Dan","family":"Hasson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 1 Department of Oncological Sciences, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 6 Tisch Cancer Institute, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 7 Bioinformatics for Next Generation Sequencing (BiNGS) Core, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0560-5543","authenticated-orcid":false,"given":"Nishant","family":"Gandhi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wh5hg83","id-type":"ROR","asserted-by":"publisher"}],"name":"Caris Life Sciences 3 , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4673-7481","authenticated-orcid":false,"given":"Triparna","family":"Sen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028t46f04","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Comprehensive Cancer Center 2 Division of Medical Oncology, Department of Internal Medicine, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091110254095700_bib1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"2026091110254095700_bib2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-024-04562-0","article-title":"Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment","volume":"166","author":"Averbuch","year":"2024","journal-title":"J Neurooncol"},{"key":"2026091110254095700_bib3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"key":"2026091110254095700_bib4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"2026091110254095700_bib5","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.3390\/cancers14194562","article-title":"Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance","volume":"14","author":"Ashrafi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026091110254095700_bib6","doi-asserted-by":"publisher","first-page":"1366260","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front Immunol"},{"key":"2026091110254095700_bib7","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.drup.2025.101215","article-title":"Resistance to immunotherapy in non-small cell lung cancer: unraveling causes, developing effective strategies, and exploring potential breakthroughs","volume":"81","author":"Dong","year":"2025","journal-title":"Drug Resist Updat"},{"key":"2026091110254095700_bib8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026091110254095700_bib9","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.3390\/cancers15153980","article-title":"Targeting cell signaling pathways in lung cancer by bioactive phytocompounds","volume":"15","author":"Choudhary","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091110254095700_bib10","doi-asserted-by":"publisher","first-page":"e2319429121","DOI":"10.1073\/pnas.2319429121","article-title":"Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer","volume":"121","author":"Han","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091110254095700_bib11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1535-7163.MCT-24-0213","article-title":"Targeting monounsaturated fatty acid metabolism for radiosensitization of KRAS mutant 3D lung cancer models","volume":"24","author":"Lu","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026091110254095700_bib12","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.celrep.2020.108444","article-title":"Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer","volume":"33","author":"Wohlhieter","year":"2020","journal-title":"Cell Rep"},{"key":"2026091110254095700_bib13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026091110254095700_bib14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11515-014-1302-6","article-title":"Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition","volume":"9","author":"Zhang","year":"2014","journal-title":"Front Biol (Beijing)"},{"key":"2026091110254095700_bib15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41389-026-00608-2","article-title":"The oncogenic control of nucleotide synthesis","volume":"15","author":"Vidal-Cruchez","year":"2026","journal-title":"Oncogenesis"},{"key":"2026091110254095700_bib16","doi-asserted-by":"publisher","first-page":"eabn1382","DOI":"10.1126\/sciadv.abn1382","article-title":"RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition","volume":"8","author":"Nunes","year":"2022","journal-title":"Sci Adv"},{"key":"2026091110254095700_bib17","doi-asserted-by":"publisher","first-page":"216993","DOI":"10.1016\/j.canlet.2024.216993","article-title":"Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor","volume":"596","author":"Chow","year":"2024","journal-title":"Cancer Lett"},{"key":"2026091110254095700_bib18","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s13277-013-1255-4","article-title":"Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"2026091110254095700_bib19","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.2147\/OTT.S162667","article-title":"RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine","volume":"11","author":"Chen","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2026091110254095700_bib20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cca.2018.05.042","article-title":"Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: a meta-analysis","volume":"485","author":"Zhu","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2026091110254095700_bib21","doi-asserted-by":"publisher","first-page":"e145099","DOI":"10.1172\/JCI145099","article-title":"Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer","volume":"132","author":"Nanjo","year":"2022","journal-title":"J Clin Invest"},{"key":"2026091110254095700_bib22","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-24-2745","article-title":"SCD1 inhibition blocks the AKT-NRF2-SLC7A11 pathway to induce lipid metabolism remodeling and ferroptosis priming in lung adenocarcinoma","volume":"85","author":"Sen","year":"2025","journal-title":"Cancer Res"},{"key":"2026091110254095700_bib23","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/ncomms8389","article-title":"Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities","volume":"6","author":"Kollareddy","year":"2015","journal-title":"Nat Commun"},{"key":"2026091110254095700_bib24","doi-asserted-by":"publisher","first-page":"41422","DOI":"10.18632\/oncotarget.17440","article-title":"P53 suppresses ribonucleotide reductase via inhibiting mTORC1","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"2026091110254095700_bib25","doi-asserted-by":"publisher","first-page":"13349","DOI":"10.18632\/aging.202962","article-title":"Emerging roles of nucleotide metabolism in cancer development: progress and prospect","volume":"13","author":"Ma","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"2026091110254095700_bib26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s43018-024-00771-8","article-title":"Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance","volume":"5","author":"Scolaro","year":"2024","journal-title":"Nat Cancer"},{"key":"2026091110254095700_bib27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/cancers12061475","article-title":"Non-small-cell lung cancer signaling pathways, metabolism, and PD-1\/PD-L1 antibodies","volume":"12","author":"Santarpia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026091110254095700_bib28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N Engl J Med"},{"key":"2026091110254095700_bib29","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.7150\/jca.47895","article-title":"Independent prognostic implications of RRM2 in lung adenocarcinoma","volume":"11","author":"Ma","year":"2020","journal-title":"J Cancer"},{"key":"2026091110254095700_bib30","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/genes12071096","article-title":"Hydroxyurea-the good, the bad and the ugly","volume":"12","author":"Musia\u0142ek","year":"2021","journal-title":"Genes (Basel)"},{"key":"2026091110254095700_bib31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.molonc.2016.07.008","article-title":"A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity","volume":"10","author":"Crona","year":"2016","journal-title":"Mol Oncol"},{"key":"2026091110254095700_bib32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","article-title":"ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway","volume":"21","author":"Chu","year":"2019","journal-title":"Nat Cell Biol"},{"key":"2026091110254095700_bib33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41420-022-01140-z","article-title":"Knockdown of RRM1 in tumor cells promotes radio-\/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis","volume":"8","author":"Gao","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026091110254095700_bib34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/biom12060815","article-title":"Inhibitors of the cancer target ribonucleotide reductase, past and present","volume":"12","author":"Huff","year":"2022","journal-title":"Biomolecules"},{"key":"2026091110254095700_bib35","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"2026091110254095700_bib36","doi-asserted-by":"publisher","first-page":"e202101157","DOI":"10.26508\/lsa.202101157","article-title":"Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity","volume":"5","author":"Tarangelo","year":"2022","journal-title":"Life Sci Alliance"},{"key":"2026091110254095700_bib37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12935-020-01689-8","article-title":"RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"2026091110254095700_bib38","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.4161\/cc.6.16.4572","article-title":"Cell cycle- and ribonucleotide reductase-driven changes in mtDNA copy number influence mtDNA inheritance without compromising mitochondrial gene expression","volume":"6","author":"Lebedeva","year":"2007","journal-title":"Cell Cycle"},{"key":"2026091110254095700_bib39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbrc.2011.05.114","article-title":"Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells","volume":"410","author":"Wang","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"2026091110254095700_bib40","first-page":"3635","article-title":"Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer","volume":"10","author":"Xue","year":"2018","journal-title":"Am J Transl Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0829\/3826006\/crc-25-0829.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2136\/3829148\/crc-25-0829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2136\/3829148\/crc-25-0829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:25:47Z","timestamp":1789136747000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2136\/788028\/Ribonucleotide-Reductase-Inhibition-Triggers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0829","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8708859","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33618717","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618714","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618747","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618759","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618708","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618738","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618729","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618720","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618765","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618732","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618744","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618756","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618735","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618750","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618723","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618762","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618741","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618711","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33618753","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}